Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (221-230 of 273) with videos related to

Pageof 28
Sort By:
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
Blood|September 26, 2012
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Blood|December 17, 2015
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsAbraham S Kanate, Alberto Mussetti, Mohamed A Kharfan-Dabaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Pageof 28

Showing results (221-230 of 273) with videos related to

Sort By:
Pageof 28
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
Blood|September 26, 2012
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Blood|December 17, 2015
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsAbraham S Kanate, Alberto Mussetti, Mohamed A Kharfan-Dabaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Pageof 28